Oncology is printing money. There is no other therapy area in global pharma that even comes close to the numbers being put up by cancer drugs right now.
This post isn't about defining what pipeline intelligence is. It's about what it does, specifically, the seven strategic advantages it gives pharma manufacturers who choose to act on it rather than admire it from a distance.
India makes a lot of medicine. A LOT. It ships pills, syrups, and injections to more than 200 countries.
Data is no longer optional. It is the engine of modern drug development. The question is whether your organization is driving it, or being left behind by it.
Biologic medicines changed modern healthcare. They treat complex diseases like cancer, autoimmune disorders, and diabetes.
Pharma R&D waste is often mistaken for scientific failure. In reality, a large portion of it is strategic and preventable.
The generic injectable market is not glamorous. It is not trendy either. But it prints money.
The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent cliffs are coming one after another, biologics are losing exclusivity across the world, and every pharma company wants a piece of the action.
Discover the latest trends in drug discovery and development for 2026, including AI-driven research, advanced clinical trial technologies, precision medicine innovations, and emerging pharma strategies shaping the future of healthcare.
Bottom line is, 2026 will is going to be one of the most important years for healthcare sector. So let’s dive in, and get a better look at what next year have up it’s sleeves.
30 April 2026
24 April 2026
10 April 2026
2 April 2026
12 March 2026
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com